Sohail Rao

Biography

Dr. Rao currently serves as Executive Vice President, DHR Health System and President and Chief
Executive Officer, DHR Health Institute for Research & Development. He is Clinical Professor (Adjunct), Irma Lerma Rangel College of Pharmacy, Texas A&M University. He also serves as a Principal Investigator of a number of clinical studies funded by NIH and other Federal agencies. 

Dr. Rao obtained his MD from Dow Medical College; his MA in Physiology from Boston University, School of Medicine and Doctorate in Philosophy (DPhil) from the Wolfson College, University of Oxford, UK.

Prior to joining DHR Health, Dr. Rao served as the System Vice President for Research and Academics and Chief Academic Officer, CHRISTUS Health. He also served as Executive Director, CHRISTUS Institute for Innovation & Advanced Clinical Care, CHRISTUS Health and the Designated Institutional Official for Accreditation Council for Graduate Medical Education. Additionally, he also served as the Academic Physician Leader, CHRISTUS Physician Group and the CHRISTUS Trinity Clinic.

Prior to serving CHRISTUS Health, Dr. Rao served as System Vice President for Research, Ochsner Health System, New Orleans, Louisiana. He also served as the Professor and Deputy Head of Schools Research, Ochsner Clinical School, University of Queensland. In this capacity, he was responsible for providing leadership of a basic, translational and clinical research enterprise across the system, which included (but not limited to) the Office of Research with over 140 employees, Center for Clinical Research (with over 50 clinical coordinators), Center for Basic and Translational Research, Core Facilities, Ochsner Cancer Research Center, Ochsner Neurosciences Research Center, Ochsner Cardiovascular Research Center, Ochsner Transplantation Research Center, Ochsner Center for Women’s Health Research, Ochsner Center for Pediatric Research, Center for Applied Health Sciences, Center for Medical Informatics, Center for Investigator Education and Training, Center for Investigator Support, Phase I-IV Clinical Trial Units (https://research.ochsner.org/clinical-research/ctu/), and facilities for BioBanking (https://research.ochsner.org/clinical-research/biobank), animal care and use facilities (both small and large animals), etc. Under his leadership, Ochsner conducted over 1000 clinical trials/year and successfully obtained AAHRPP accreditation of its Human Subject Research Protection Program as well as implement a state-of-the-art clinical trials management system which was instrumental in improving compliance.

During his tenure at Ochsner, Dr. Rao also served as the Vice President, Ochsner International. In this capacity, Dr. Rao was responsible for all international outreach in the MENA (Middle East and North America) region related to clinical, research, undergraduate and graduate education in medicine, nursing, pharmacy, and allied health sciences. On behalf of Ochsner, he also served as the consultant to facilitate the establishment of two universities, a medical city and two university hospitals in the Kingdom of Saudi Arabia.

Prior to coming to Ochsner, Dr. Rao served University of South Florida Health (USF Health) as Professor of Surgery and Molecular Medicine. He was also the Senior Associate Vice President at USF Health and served as the Chief Research Officer for this academic entity. His areas of oversight included the Colleges of Medicine, Nursing, Public Health and Physical Medicine and Rehabilitation. He was also the Vice Dean for Research, Graduate and Postdoctoral Affairs in the College of Medicine, Founding Director of the School of Biomedical Sciences, and Medical Director for Research at the Tampa General Hospital, Tampa, Florida. During his tenure at USF, he also served as the Chief Operating Officer, Byrd Alzheimer’s Institute. His principal task at USF Health was to raise the NIH profile of funding for the health sciences, which culminated in the recruitment of outstanding faculty, departmental mergers and a complete redesign of the faculty appointment and tenure process. In 2017, he also served as the Vice Chair of the LCME self-study team, which was successful in obtaining continued accreditation of the medical school.

After completing his doctoral education at Oxford, Dr. Rao joined the University of Pittsburgh in 1993 where he served as an Associate Professor, Department of Surgery, School of Medicine, University of Pittsburgh and the Director and Chief of the Section of Cellular Transplantation and the Section of Medical Informatics, Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center. During his tenure in Pittsburgh, he also served as the Associate Director, Thomas E. Starzl Transplant Institute where he was tasked with establishing and subsequently providing strategic and operational oversight of the world’s largest transplant program.

In 2000, he joined Drexel University, College of Medicine (previously named as MCP Hahnemann University School of Medicine) as the Senior Associate Dean for Research and Biomedical Graduate Studies and Professor in the Departments of Surgery, and Microbiology and Immunology. He subsequently became the Vice Dean for Research and Graduate Studies at Drexel University College of Medicine and in 2003, was promoted to the position of the Senior Associate Vice Provost for Research and Graduate Studies at Drexel University. He and his team were tasked with the responsibility of turning around a bankrupt medical school, which was successfully accomplished.

In 2004, he joined the Middle Tennessee State University; the largest comprehensive institution of higher education in the Tennessee Board of Regents System (the Nation’s sixth largest higher education system) where he served as Vice Provost for Research and Dean, College of Graduate Studies. During his tenure in Tennessee, he also served as the Chair, System-wide Research & Graduate Education Committee and was instrumental in initiating (among others) doctoral programs in English Literature, Molecular Sciences; Literacy Studies; Computational Sciences; Economics and Human Performance and MBA (with concentration in Healthcare Management) and Masters of Fine Arts in Recording Arts & Technology.

His area of research interest largely focused on bench to bedside (and reverse) translation of novel therapeutic strategies aimed at alleviating a clinical problem. In the area of clinical research, he and his group have worked on the protocol for induction of donor-specific tolerance in organ allograft recipients (funded by NIH); cellular therapeutic treatment of refractory post transplant lymphoproliferative disorders (funded by CTRF); islet cell transplantation to reverse type I insulin-dependent diabetes (funded by NIH and the JDFI); transmission of infection following animals to humans (funded by an extramural grant) organ and cell transplantation. Additionally, his group has also been actively involved in basic cellular and molecular biology research in the following areas: induction of tolerance, islet cell transplantation, NK cell immunobiology, post-transplant vasculopathy (chronic rejection); liver-derived growth factors; generation of transgenic pigs and xenotransplantation. His recent research interests involve prevention and treatment of HIV/AIDS, cervical cancer, Sexually Transmitted Diseases and other communicable diseases.

To his credit are over 140 publications in peer-reviewed journals and numerous book chapters. He has presented or has been invited to present >400 lectures on various issues related to his area of expertise. He has served on the editorial board of the journal Transplantation and Graft. He has served as the reviewer for Immunology, Life Sciences, Nature Medicine, Liver Transplantation Surgery, and Surgery. He has served as a mentor for >50 junior faculty and post-doctoral fellows, and >20 pre-doctoral candidates. For his team's innovative discoveries, he has been interviewed by the CNN, Discovery Channel, and many local, national, and international television, radio, and print media.

For his contributions to science, teaching, public service and for his scholarly distinction, in 2005, Dr. Rao was also selected as a Senior Scholar by Phi Kappa Phi, the nation's oldest, largest, and most selective honor society for all academic disciplines.